175 related articles for article (PubMed ID: 35364627)
1. USP28 enables oncogenic transformation of respiratory cells, and its inhibition potentiates molecular therapy targeting mutant EGFR, BRAF and PI3K.
Prieto-Garcia C; Hartmann O; Reissland M; Braun F; Bozkurt S; Pahor N; Fuss C; Schirbel A; Schülein-Völk C; Buchberger A; Calzado Canale MA; Rosenfeldt M; Dikic I; Münch C; Diefenbacher ME
Mol Oncol; 2022 Sep; 16(17):3082-3106. PubMed ID: 35364627
[TBL] [Abstract][Full Text] [Related]
2. The deubiquitinase USP28 controls intestinal homeostasis and promotes colorectal cancer.
Diefenbacher ME; Popov N; Blake SM; Schülein-Völk C; Nye E; Spencer-Dene B; Jaenicke LA; Eilers M; Behrens A
J Clin Invest; 2014 Aug; 124(8):3407-18. PubMed ID: 24960159
[TBL] [Abstract][Full Text] [Related]
3. Loss of USP28-mediated BRAF degradation drives resistance to RAF cancer therapies.
Saei A; Palafox M; Benoukraf T; Kumari N; Jaynes PW; Iyengar PV; Muñoz-Couselo E; Nuciforo P; Cortés J; Nötzel C; Kumarakulasinghe NB; Richard JLC; Bin Adam Isa ZF; Pang B; Guzman M; Siqin Z; Yang H; Tam WL; Serra V; Eichhorn PJA
J Exp Med; 2018 Jul; 215(7):1913-1928. PubMed ID: 29880484
[TBL] [Abstract][Full Text] [Related]
4. Maintaining protein stability of ∆Np63 via USP28 is required by squamous cancer cells.
Prieto-Garcia C; Hartmann O; Reissland M; Braun F; Fischer T; Walz S; Schülein-Völk C; Eilers U; Ade CP; Calzado MA; Orian A; Maric HM; Münch C; Rosenfeldt M; Eilers M; Diefenbacher ME
EMBO Mol Med; 2020 Apr; 12(4):e11101. PubMed ID: 32128997
[TBL] [Abstract][Full Text] [Related]
5. Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR.
Prahallad A; Sun C; Huang S; Di Nicolantonio F; Salazar R; Zecchin D; Beijersbergen RL; Bardelli A; Bernards R
Nature; 2012 Jan; 483(7387):100-3. PubMed ID: 22281684
[TBL] [Abstract][Full Text] [Related]
6. Mutationally activated PIK3CA(H1047R) cooperates with BRAF(V600E) to promote lung cancer progression.
Trejo CL; Green S; Marsh V; Collisson EA; Iezza G; Phillips WA; McMahon M
Cancer Res; 2013 Nov; 73(21):6448-61. PubMed ID: 24019382
[TBL] [Abstract][Full Text] [Related]
7. USP28: Oncogene or Tumor Suppressor? A Unifying Paradigm for Squamous Cell Carcinoma.
Prieto-Garcia C; Tomašković I; Shah VJ; Dikic I; Diefenbacher M
Cells; 2021 Oct; 10(10):. PubMed ID: 34685632
[TBL] [Abstract][Full Text] [Related]
8. Mitogen-Inducible Gene-6 Mediates Feedback Inhibition from Mutated BRAF towards the Epidermal Growth Factor Receptor and Thereby Limits Malignant Transformation.
Milewska M; Romano D; Herrero A; Guerriero ML; Birtwistle M; Quehenberger F; Hatzl S; Kholodenko BN; Segatto O; Kolch W; Zebisch A
PLoS One; 2015; 10(6):e0129859. PubMed ID: 26065894
[TBL] [Abstract][Full Text] [Related]
9. USP28 deletion and small-molecule inhibition destabilizes c-MYC and elicits regression of squamous cell lung carcinoma.
Ruiz EJ; Pinto-Fernandez A; Turnbull AP; Lan L; Charlton TM; Scott HC; Damianou A; Vere G; Riising EM; Da Costa C; Krajewski WW; Guerin D; Kearns JD; Ioannidis S; Katz M; McKinnon C; O'Connell J; Moncaut N; Rosewell I; Nye E; Jones N; Heride C; Gersch M; Wu M; Dinsmore CJ; Hammonds TR; Kim S; Komander D; Urbe S; Clague MJ; Kessler BM; Behrens A
Elife; 2021 Oct; 10():. PubMed ID: 34636321
[TBL] [Abstract][Full Text] [Related]
10. Ubiquitin-specific protease 28 is overexpressed in human glioblastomas and contributes to glioma tumorigenicity by regulating MYC expression.
Wang Z; Song Q; Xue J; Zhao Y; Qin S
Exp Biol Med (Maywood); 2016 Feb; 241(3):255-64. PubMed ID: 26209720
[TBL] [Abstract][Full Text] [Related]
11. Targeting c-MYC through Interference with NAMPT and SIRT1 and Their Association to Oncogenic Drivers in Murine Serrated Intestinal Tumorigenesis.
Brandl L; Zhang Y; Kirstein N; Sendelhofert A; Boos SL; Jung P; Greten F; Rad R; Menssen A
Neoplasia; 2019 Oct; 21(10):974-988. PubMed ID: 31442917
[TBL] [Abstract][Full Text] [Related]
12. MicroRNA-216b suppresses the cell growth of hepatocellular carcinoma by inhibiting Ubiquitin-specific peptidase 28 expression.
Zhang JF
Kaohsiung J Med Sci; 2020 Jun; 36(6):423-428. PubMed ID: 32053284
[TBL] [Abstract][Full Text] [Related]
13. Blocking EGFR palmitoylation suppresses PI3K signaling and mutant KRAS lung tumorigenesis.
Kharbanda A; Walter DM; Gudiel AA; Schek N; Feldser DM; Witze ES
Sci Signal; 2020 Mar; 13(621):. PubMed ID: 32127496
[TBL] [Abstract][Full Text] [Related]
14. Knockdown of USP28 enhances the radiosensitivity of esophageal cancer cells via the c-Myc/hypoxia-inducible factor-1 alpha pathway.
Weili Z; Zhikun L; Jianmin W; Qingbao T
J Cell Biochem; 2019 Jan; 120(1):201-212. PubMed ID: 30206969
[TBL] [Abstract][Full Text] [Related]
15. MYC synergizes with activated BRAFV600E in mouse lung tumor development by suppressing senescence.
Tabor V; Bocci M; Alikhani N; Kuiper R; Larsson LG
Cancer Res; 2014 Aug; 74(16):4222-9. PubMed ID: 24934810
[TBL] [Abstract][Full Text] [Related]
16. Resistance to BRAF inhibition in BRAF-mutant colon cancer can be overcome with PI3K inhibition or demethylating agents.
Mao M; Tian F; Mariadason JM; Tsao CC; Lemos R; Dayyani F; Gopal YN; Jiang ZQ; Wistuba II; Tang XM; Bornman WG; Bollag G; Mills GB; Powis G; Desai J; Gallick GE; Davies MA; Kopetz S
Clin Cancer Res; 2013 Feb; 19(3):657-67. PubMed ID: 23251002
[TBL] [Abstract][Full Text] [Related]
17. BGB-283, a Novel RAF Kinase and EGFR Inhibitor, Displays Potent Antitumor Activity in BRAF-Mutated Colorectal Cancers.
Tang Z; Yuan X; Du R; Cheung SH; Zhang G; Wei J; Zhao Y; Feng Y; Peng H; Zhang Y; Du Y; Hu X; Gong W; Liu Y; Gao Y; Liu Y; Hao R; Li S; Wang S; Ji J; Zhang L; Li S; Sutton D; Wei M; Zhou C; Wang L; Luo L
Mol Cancer Ther; 2015 Oct; 14(10):2187-97. PubMed ID: 26208524
[TBL] [Abstract][Full Text] [Related]
18. Modeling tumor progression by the sequential introduction of genetic alterations into the genome of human normal cells.
Zecchin D; Arena S; Martini M; Sassi F; Pisacane A; Di Nicolantonio F; Bardelli A
Hum Mutat; 2013 Feb; 34(2):330-7. PubMed ID: 23292961
[TBL] [Abstract][Full Text] [Related]
19. Copper is required for oncogenic BRAF signalling and tumorigenesis.
Brady DC; Crowe MS; Turski ML; Hobbs GA; Yao X; Chaikuad A; Knapp S; Xiao K; Campbell SL; Thiele DJ; Counter CM
Nature; 2014 May; 509(7501):492-6. PubMed ID: 24717435
[TBL] [Abstract][Full Text] [Related]
20. USP28 promotes tumorigenesis and cisplatin resistance by deubiquitinating MAST1 protein in cancer cells.
Karapurkar JK; Colaco JC; Suresh B; Tyagi A; Woo SH; Jo WJ; Ko N; Singh V; Hong SH; Oh SJ; Kim KS; Ramakrishna S
Cell Mol Life Sci; 2024 Mar; 81(1):145. PubMed ID: 38498222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
